HomeProductsBioactive CompoundsGPCR & G Protein TargetsBradykinin ReceptorAnatibant
Chemical structure of CAS 209733-45-9

Anatibant

CAS No.209733-45-9
MDL No.N/A
MFC34H36Cl2N6O5S
MW711.70
InChI KeyXUHBBTKJWIBQMY-MHZLTWQESA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Anatibant is a proline derivative.

CAS No.209733-45-9
Product NameAnatibant

Biological Targets

BDKRB2
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.

Trials • Vol. 10 • 2009
PMID: 19958521PMC: PMC2794266DOI: 10.1186/1745-6215-10-109

Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury.

Trials • Vol. 10 • 2009
PMID: 19958522PMC: PMC2797007DOI: 10.1186/1745-6215-10-110

Anatibant, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury.

Neuroscience letters • Vol. 454, Issue 2 • 2009
PMID: 19429066DOI: 10.1016/j.neulet.2009.02.014

Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome.

Critical care medicine • Vol. 37, Issue 7 • 2009
PMID: 19487935DOI: 10.1097/CCM.0b013e3181a068fc

Documentation

Similar Products